title: [Chemotherapy-induced peripheral neuropathy].
abstract: Chemotherapy-induced peripheral neuropathy(CIPN)is one of chemotherapy's common and disabling adverse effects. It may be caused by many chemotherapeutic agents including the taxanes(paclitaxel, docetaxel), the vinca alkaloids(vincristine, vinorelbine, vinblastine), the platinum analogues(cisplatin, carboplatin, oxaliplatin), bortezomib and thalidomide, among others. Once the symptoms have developed, they may lead to compromising patients' quality of life(QOL). For medical oncologists, the management of CIPN remains an important challenge. At the present time, no agent has shown enough solid beneficial evidence to be recommended for the treatment or/prophylaxis of CIPN. The standard of care for CIPN includes awareness and early detection of neuropathy, and dose reduction and/or discontinuation of the problematic agents.
authors.affiliation: Dept. of Chemotherapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Tokyo, Japan.
authors.forename: Emi
authors.initials: E
authors.lastname: Noguchi
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Maeda
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D011788:Quality of Life; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents